BioCentury | Apr 2, 2020
Finance

Dynacure taps U.S. crossovers in €50M series C to fund orphan muscle disease studies

...BIN1 - Bridging integrator 1 DMN2 - Dynamin 2 MTM1 - Myotubularin 1 Paul Bonanos, Associate Editor DYN101...
BioCentury | Jul 13, 2018
Financial News

French Orphan company Dynacure raises €47M

...million ($2.3 million) seed round from Kurma. Launched in 2016, Dynacure is developing lead program Dyn101...
BioCentury | Jul 6, 2018
Financial News

French Orphan company Dynacure raises €47M

...million ($2.3 million) seed round from Kurma. Launched in 2016, Dynacure is developing lead program Dyn101...
...Institute of Genetic and Molecular and Cellular Biology (IGBMC) in France (see "Kurma Chameleon" ). Paul Bonanos DYN101...
BioCentury | Jul 6, 2018
Finance

Dynacure’s quick transfer

...oligonucleotide that showed efficacy in mice at IGBMC. In November 2017, the company selected candidate Dyn101...
...A pivotal U.S. and European Phase II/III study would follow. The company hopes to develop Dyn101...
BioCentury | Nov 17, 2017
Company News

Ionis grants Dynacure rights to musculoskeletal candidate IONIS-DNM2-2.5Rx

...Ionis Pharmaceuticals Inc. (NASDAQ:IONS) granted Dynacure S.A.S. (Illkirch, France) rights to develop and commercialize IONIS-DNM2-2.5Rx (DYN101...
...to inquiries. Ionis Pharmaceuticals Inc. (NASDAQ:IONS), Carlsbad, Calif. Dynacure S.A.S., Illkirch, France Business: Musculoskeletal Jaime De Leon DYN101 IONIS-DNM2-2.5Rx Dynacure...
BioCentury | Jun 21, 2017
Distillery Therapeutics

Musculoskeletal

...with established disease, the ASO decreased muscle pathology. Ongoing studies by Dynacure S.A.S. include testing DYN101...
...in non-human primates and mice expressing that gene. Dynacure S.A.S. and Ionis Pharmaceuticals Inc. have DYN101...
Items per page:
1 - 6 of 6